One other biotech will declare phase III testing results on March 31, the stock is up big already, straddle was suggested in this one a few hours ago. Could be cut in half, move up handsomely or be a non-event. Its hard to resist some of these, but you have to separate the real gold from the fool's gold. Volume in this other is also about 3 times average, but the other is not 16% above the year high. Its good watching these as well, but not put all your golden eggs in one basket. We find that the value stocks will make better plays and unlike NVEC, will usually NOT get the carpet pulled out viciously from under you (i.e. CECO, GE, SNDK, RIMM, TASR etc are fine, NVEC is a devil) Certainly more interesting then the semiconductors day in and day out.
The occasional "specialty play" is nice too. We didn't really take TASR as a swing until January 2004, so I never held for more than a few days at a time although it was traded frequently it was forgotten at failures to break out of consolidation. Its important to track these plays at the very first break out of consolidation because that leads to another leg up for the most part.
Once options came out in TASR, it was 'couldn't buy enough of this baby'. IDSA was a nice breakout play and we called the breakout but I doubt anyone held thisthrough the weekend (principly because it was not an extended play, wasn't called a swing play officially in the trading room or via emailed updates, as we had what we thought at the time were more solid plays)
Market Data 
Markets 
AI
